Search Results
Jun 11, 2026, 08:42 ET Fractal Launches Cogentiq E-Commerce: AI that Acts on Profit Signals in Minutes
Qure.ai, a global healthcare AI leader enhancing the rapid identification and management of tuberculosis, lung cancer, and stroke. Fractal's dedicated AI Research team is focused on foundational
More news about: Fractal Analytics Limited
Jun 11, 2026, 08:30 ET Fractal Launches Cogentiq E-Commerce: AI that Acts on Profit Signals in Minutes
Qure.ai, a global healthcare AI leader enhancing the rapid identification and management of tuberculosis, lung cancer, and stroke. Fractal's dedicated AI Research team is focused on foundational
More news about: Fractal Analytics Limited
Jun 11, 2026, 08:11 ET Oncura Health Physicians Recognized for Research Contributions at ASCO 2026
COPERNICUS Phase 2b study evaluating subcutaneous amivantamab in combination with chemotherapy for patients with EGFR-mutated advanced non-small cell lung cancer.In addition, Dr. Seneviratne was a named contributor on a poster presentation titled "Achieving epidemiologically representative enrollment
More news about: Oncura Health
Jun 11, 2026, 04:22 ET Peer-reviewed publication shows that Lateral pharma's SCP drugs for neuropathic pain act via the novel target LanCL1
published research in Mucosal Immunology demonstrating that LAT9997, Lateral Pharma's lead SCP peptide, significantly improved survival and reduced lung injury in preclinical models of influenza-associated bacterial pneumonia. In that study, two intranasal doses of LAT9997 administered during the early
More news about: Lateral Pharma
Jun 11, 2026, 02:20 ET CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) ASCO 2026 Key Highlights
anti-tumor activity has been observed in several traditionally immunotherapy-insensitive tumor types, including: Immunotherapy-resistant non-small cell lung cancer (NSCLC), pMMR/MSS metastatic colorectal cancer (mCRC), Soft tissue sarcoma (STS), Non-clear cell renal cell carcinoma (nccRCC).These findings
More news about: CStone Pharmaceuticals
Jun 10, 2026, 15:01 ET Children's Hospital of Philadelphia Study May Help Explain Why Some Children with Sepsis or Organ Failure Face a Harder Recovery
Center for Translational Lung Biology at the
More news about: Children's Hospital of Philadelphia
Jun 10, 2026, 12:20 ET Deerfield Management Announces Portfolio Company Nuvalent, Inc. to be Acquired by GSK
patients."With two late-stage, potential best-in-class, next-generation, highly selective ROS1 and ALK inhibitors for treatment of non-small cell lung cancer, Nuvalent is advancing a pipeline of additional small molecules with the goal to overcome resistance, minimize adverse events, address brain
More news about: Deerfield Management Company, L.P.
Jun 10, 2026, 11:13 ET Ten California students advance to national finals of the Mott Million Dollar Challenge in Flint, Michigan
wearable, beamforming-enabled stethoscope array that uses advanced sensors, signal processing and machine learning to improve the detection of heart and lung conditions.Scam Savvy — Camil Gallardo and Andy Yu (11th Grade, Galileo Academy of Science & Technology), business
More news about: Charles Stewart Mott Foundation
Jun 10, 2026, 09:01 ET HOPPR to Showcase Pioneering Catalyst Research Projects at SIIM26, Open Applications for New Cohort
University of Illinois Cancer Center are using the HOPPR® AI Foundry to advance projects spanning breast cancer detection, lung cancer prediction, and fracture detection.HOPPR's Catalyst Program is now open for applications, helping radiologists, researchers,
More news about: HOPPR
Jun 10, 2026, 09:00 ET IMMP Deadline Alert: Levi & Korsinsky Reminds Immutep Limited (IMMP) Investors of Securities Class Action Deadline on July 6, 2026
management's repeated assurances about TACTI-004's trajectory. Throughout the Class Period, the lawsuit contends, the Company described its pivotal Phase III lung cancer trial as exhibiting "strong operational progress" and highlighted enrollment milestones, investigator enthusiasm, and FDA regulatory clearance.
More news about: Levi & Korsinsky, LLP
Jun 10, 2026, 08:40 ET Radon Mitigation Cost in Southern Minnesota Explained in HelloNation, featuring Radon Expert Mitch Kelley
system for their property.Health considerations are also addressed in the article. Radon exposure is identified as the second leading cause of lung cancer, making mitigation an important investment rather than an optional upgrade. The HelloNation article encourages homeowners to weigh the long-term
More news about: HelloNation
Jun 09, 2026, 22:13 ET Rakuten Medical Announces Executive Leadership Transition to Enhance Operational Execution and Organizational Discipline as a Global, Scalable Biotech Company
700DX, a light activatable dye. ASP-1929 binds to EGFR, a cancer antigen expressed in multiple types of solid tumors, including head and neck, breast, lung, colorectal, prostate and pancreatic cancers. After binding to cancer cells, ASP-1929 is locally activated by illumination with red light (690 nm), emitted
More news about: Rakuten Medical, Inc.
Jun 09, 2026, 21:06 ET IMMP Investor Alert - Immutep Limited Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action Lawsuit
The company's product pipeline includes TACTI-004, which is in phase III clinical trial evaluating eftilagimod alfa (efti) in patients with advanced lung cancer.For more information, submit a
More news about: Robbins LLP
Jun 09, 2026, 21:00 ET Antengene Receives IND Approval for ATG-201 (CD19 × CD3 TCE) in Autoimmune Disease in China
documents subsequently submitted to the Hong Kong Stock Exchange.For more information, please contact:Investor Contacts: Donald LungE-mail: [email protected] BD Contacts:Ariel
More news about: Antengene Corporation Limited
Jun 09, 2026, 09:31 ET Lung Cancer Research Foundation and AstraZeneca Announce Open Call for Research Proposals with Focus on Small Cell Lung Cancer
Two Lung Cancer Research Grants Aim to Accelerate Discoveries and Enhance Outcomes in Small Cell Lung Cancer TreatmentNEW YORK, June 9, 2026 /PRNewswire/ -- The Lung Cancer Research Foundation (LCRF), in collaboration
More news about: Lung Cancer Research Foundation
Jun 09, 2026, 09:30 ET Lung Cancer Research Foundation Announces Request for Proposals Open for ALK-Positive Lung Cancer Research Grant
ALK-Positive Lung Cancer grant was made possible by funding from members of the lung cancer community, led by Colleen Conner Ziegler, chair of LCRF's board of directors and ALK-positive lung cancer survivor; the Murgatroyd family, who lost their daughter at the age of 24 to ALK-positive lung cancer;
More news about: Lung Cancer Research Foundation
Jun 09, 2026, 08:23 ET First Patients Dosed in Phase 2 SIRIUS COPD Study of HBM9378/WIN378, a Fully Human Ultra Long-Acting Anti-TSLP Antibody
COPD is a progressive, irreversible lung disease and the third leading cause of death worldwide. Driven by immune-mediated airway inflammation and persistent airflow obstruction, the disease
More news about: Harbour BioMed
Jun 09, 2026, 08:14 ET Kelun-Biotech Partner Windward Bio Announces First Patients Dosed in Phase 2 SIRIUS COPD Study of SKB378/WIN378
COPD is a progressive, irreversible lung disease and the third leading cause of death worldwide. Driven by immune-mediated airway inflammation and persistent airflow obstruction, the disease
More news about: Kelun-Biotech
Jun 09, 2026, 08:00 ET Matica Biotechnology announces engagement by University Health Network (UHN) to supply cGMP Manufacturing of IL-10 Adenoviral Therapy for Lung Transplantation
includes cGMP manufacturing of an interleukin-10 (IL-10) adenoviral gene therapy designed for potential delivery to donor lungs during ex vivo lung perfusion (EVLP) prior to transplantation. Under the agreement, Matica Bio will provide comprehensive development and manufacturing services
More news about: Matica Biotechnology, Inc.
Jun 09, 2026, 05:13 ET Whole-Body Spatial Intelligence Beyond Weight-loss: nference Advances Cardiometabolism Moat for Precision Peptide Medicines and Healthy Longevity
nference MAIA team presented "Metabotypes of Pembrolizumab and Lung Cancer" and "Associations between early on-treatment weight change and overall survival across targeted therapies in chronic lymphocytic leukemia (CLL)". In the lung cancer study, early on-treatment weight gain was a favorable
More news about: nference
Jun 08, 2026, 19:00 ET China NMPA Grants IND Clearance to Adcentrx Therapeutics' ADRX-0405 STEAP1 ADC for the Treatment of Late-Stage Solid Tumors, Including Prostate Cancer
evaluating ADRX-0405 in patients with late-stage solid tumors, including metastatic castration resistant prostate cancer, gastric cancer, and non-small cell lung cancer.
More news about: Adcentrx Therapeutics
Jun 08, 2026, 16:07 ET Tampa General Hospital Recognized as One of America's Best Hospitals for Specialized Care in Seven Specialties by Newsweek
TGH Lung Institute) – ranked #68 nationallyGastrointestinal Care (
More news about: Tampa General Hospital
Jun 08, 2026, 10:01 ET Pneumonia Market Set to Witness Robust Growth During the Forecast Period (2026-2036), Driven by Advancing Therapeutics and Rising Disease Burden | DelveInsight
Preclinical studies have shown that AON-D21 is effective in translational models of pneumonia and sepsis, and it has also demonstrated potential in lung cancer, particularly when combined with immune checkpoint inhibitors, suggesting that modulation of C5a may have broad therapeutic applications across
More news about: DelveInsight Business Research, LLP
Jun 08, 2026, 09:05 ET Providence St. Joseph Hospital in Orange First Hospital in California to Earn 'Advanced Chronic Obstructive Pulmonary Disease Certification' from The Joint Commission
track outcomes and redesign processes focused on patient safety and improved care across inpatient and outpatient settings.COPD is a chronic lung disease that can significantly impact breathing and quality of life. Advanced COPD programs focus on coordinated, evidence-based care designed to reduce
More news about: Providence St. Joseph Hospital
Jun 08, 2026, 05:45 ET Hengrui Pharma Presents More Than 90 Oncology Studies at ASCO 2026, Highlighting Progress Across Multiple Tumor Types
the ASCO Annual Meeting. This year, the company's research program encompasses multiple key areas, including gastrointestinal cancers, breast cancer, lung cancer, urological cancers, gynecological cancers, and supportive cancer care, covering 11 approved medicines, 10 pipeline candidates, and one Class
More news about: Hengrui Pharma